drugset / Trial / NCT00466037
The Effect of Rituximab on the Humoral Response to Influenza Vaccine
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that selectively targets CD20+ B cells and induces a transient depletion of the CD20+ mature B cell subpopulation.The objective of our study was to assess the effect of rituximab on the efficacy and safety of influenza virus vaccine in patients with rheumatoid arthritis (RA).
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza Virus Vaccine | Vaccine | 15 ug | — |